When the White House made its ibogaine announcement, shares of small companies like Psyence BioMed shot up. But unless one of those companies announces a major partnership worth more than $50 million or hits a concrete trial milestone before the end of September 2026, those share prices are expected to slide back down. This pattern — a spike on political news followed by a drop when no real business progress follows — is common in speculative biotech sectors.
Headline pops without capital or data always mean-revert. No institutional money chases a government press event; I'd short the retrace.
Join our community — a free weekly Zoom circle with a master facilitator. Come sit with us first; the rest reveals itself.
Join the Free Weekly Circle →